Sibel Zehra Aydin

Sibel Zehra Aydin

Auto-generated profile, based on publicly available information

Sibel Zehra Aydin

Division of Rheumatology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2010 in Rheumatology
Verified
Journal Article
Open access
PDF file
SASibel Z. Aydin
Sibel Z. Aydin
NYNeslihan Yilmaz
Neslihan Yilmaz
SAServet Akar
Servet Akar
KAKenan Aksu
Kenan Aksu
SKSevil Kamali
Sevil Kamali
HDHaner Direskeneli
Haner Direskeneli
Objective. Disease Extent Index-Takayasu (DEI.Tak) is a new index developed for the follow-up of Takayasu’s arteritis (TA), assessing only clinical findings without the requirement of imaging. We investigated the effectiveness of DEI.Tak in assessing disease activity and progression by comparing with physician’s global assessment (PGA) and active disease criteria defined by Kerr et al. Methods. The initial DEI.Tak forms were filled in for 145 TA patients cross-sectionally to detect the baseline damage and after 29.8 (31) months (n = 105, 144 visits) only by including the new/worsening symptoms within the past 6 months. Results. At baseline, all patients had a DEI.Tak >0 [mean (s.d. ): 7.6 (4.2)]. At this evaluation, 62% of the patients had active, 16.2% had persistent and 21.8% had inactive disease according to the PGA. At follow-up, in 69% of the patients the DEI.Tak score was 0. However, 14% of them were accepted as having active and 17% persistent disease according to PGA. In contrast, 18% with a DEI.Tak ≥ 1 were inactive according to PGA. Patients with active or persistent disease with PGA had higher DEI.Tak compared with inactives [1.3 (1.9), 1 (1.3) vs 0.2 (0.6), respectively; P < 0.001]. According to Kerr’s criteria 27% were active. The total agreement between DEI.Tak and Kerr’s criteria was 94% (κ = 0.85). Compared with PGA, Kerr’s criteria had a total agreement of 74% and DEI.Tak 68%. Conclusion. During follow-up, most TA patients showed no clinical activity with DEI-Tak. Although the agreement between Kerr’s criteria and DEI.Tak seemed very good, using Kerr’s criteria instead of DEI.Tak increased the consistency with PGA, which could be explained by the influence of imaging data and acute-phase reactant levels on the physician’s decisions.

29 December 2009 in Rheumatology
Verified
Journal Article
Open access
PDF file
SASibel Zehra Aydin
Sibel Zehra Aydin
OKOmer Karadag
Omer Karadag
EFEmilio Filippucci
Emilio Filippucci
PAPamir Atagunduz
Pamir Atagunduz
AAAli Akdogan
Ali Akdogan
HDHaner Direskeneli
Haner Direskeneli
Objective. Enthesitis is considered as the primary anatomical lesion in ankylosing spondylitis (AS). Therapeutic effects of TNF-α antagonist treatments for enthesitis on imaging changes are still limited to case reports or small sample-sized trials. We aimed to investigate the potential of ultrasonography (US) to detect early changes after TNF-α antagonist therapy of Achilles enthesis of AS patients. Methods. Forty-three AS patients with active disease, requiring TNF-α antagonist therapy, were included. Physical examination was performed to detect Achilles enthesitis and/or retrocalcaneal bursitis. US of the Achilles tendon was performed bilaterally. Grey-scale (GS) and power Doppler (PD) scores on a 0–2 semi-quantitative scale and total additive scores (TS) were calculated. Follow-up US examinations were performed 2 months after the initiation of therapy. Results. At baseline, 11 patients (26.2%) were symptomatic in physical examination for either Achilles enthesitis or retrocalcaneal bursitis, whereas 36 (83%) had GS US pathological findings and 10 (23.3%) had PD signal. GS score and TS decreased significantly [3.6 (3.0) vs 2.3 (2.2), P < 0.001 and 4.7 (4.9) vs 2.7 (3.3), P < 0.001, respectively], whereas the decrease in PD score was not significant after 2 months of follow-up. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), ESR and CRP levels also showed significant improvements. Conclusions. Subclinical Achilles enthesitis, detected only with GS US, is present in a subset of AS patients and a significant improvement can be demonstrated after 2 months of TNF-α antagonist therapy. In addition to standard outcome measures, US might be an additional useful tool to monitor therapy in SpA patients with Achilles enthesitis.

1 February 2020 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
SBSibel Bakirci
Sibel Bakirci
DSDilek Solmaz
Dilek Solmaz
WSWilson Stephenson
Wilson Stephenson
LELihi Eder
Lihi Eder
JRJohannes Roth
Johannes Roth
SASibel Zehra Aydin
Sibel Zehra Aydin
Objective.: We aimed to investigate the prevalence of ultrasonographic (US) lesions in healthy entheses and contributing factors.Methods.: US scans were performed on 960 entheses of 80 healthy subjects. Factors contributing to entheseal changes were investigated with regression analysis.Results.: Thickening (20.4% of the entheses) and enthesophytes (23.1%) were the most common inflammatory and structural damage lesions, respectively. Age (p < 0.001), male sex (p = 0.003), body mass index (BMI; p = 0.001), and high physical activity (p = 0.007) were independent predictors of enthesitis scores on US.Conclusion.: The effects of age, sex, BMI, and physical activity on the entheses need to be considered when differentiating disease from health.

6 February 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ZSZiver Sahin
Ziver Sahin
MBMuge Bıcakcıgil
Muge Bıcakcıgil
KAKenan Aksu
Kenan Aksu
SKSevil Kamali
Sevil Kamali
SAServet Akar
Servet Akar
TGthe Turkish Takayasu Study Group
the Turkish Takayasu Study Group
Introduction: HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical and immunological differences. In this study, we aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as susceptibility and severity factors. Methods: TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n = 210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-specific primers. Results: We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR = 0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P = 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs 26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78). Conclusions: In this study, the previously reported association of TAK with HLA-B*52 in other populations was confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored further.

14 February 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
DPDenis Poddubnyy
Denis Poddubnyy
VNVictoria Navarro-Compán
Victoria Navarro-Compán
MTMurat Torgutalp
Murat Torgutalp
SASuzanne Arends
Suzanne Arends
SASibel Zehra Aydin
Sibel Zehra Aydin
DHDésirée van der Heijde
Désirée van der Heijde
To develop a consensus-based expert definition of difficult-to-manage (D2M) axial spondyloarthritis (axSpA), incorporating treatment-refractory (TR) disease. A literature review was conducted in 2022 to identify potential definitions for D2M/TR axSpA from prior studies, followed by a 2-round Delphi consensus process conducted in 2022 and 2023 to identify components of D2M axSpA. Based on the results of the Delphi process, a draft of the D2M axSpA definition was developed and presented to the expert task force, including patient representation, and, subsequently, to the Assessment of SpondyloArthritis International Society (ASAS) membership for endorsement in January 2024. Consensus was reached on a D2M definition encapsulating treatment failure (treatment according to the ASAS-European Alliance of Associations for Rheumatology recommendations and failure of ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action unless contraindicated), suboptimal disease control, and physician or patient acknowledgement of problematic signs/symptoms in patients diagnosed with axSpA by the rheumatologist. This definition represents a broad concept that includes various reasons that lead to an unsatisfactory treatment outcome. TR axSpA is covered by the D2M definition but requires a history of treatment failure, the presence of objective signs of inflammatory activity, and the exclusion of noninflammatory reasons for nonresponse. The proposed D2M definition incorporating TR disease was endorsed by ASAS at the annual meeting in January 2024, with 89% votes (109/123) in favour of it. The ASAS D2M axSpA definition, including TR disease, allows for identifying patients with unmet needs, paving the way for further research in this condition and its clinical care improvement.

15 February 2021 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGurjit S. Kaeley
Gurjit S. Kaeley
LELihi Eder
Lihi Eder
SASibel Zehra Aydin
Sibel Zehra Aydin
PRPhoebe Rich
Phoebe Rich
CBCatherine J. Bakewell
Catherine J. Bakewell
Objective: An estimated 40–50% of patients with psoriasis (PsO) have psoriatic nail disease, which is associated with and directly contributes to a greater clinical burden and worse quality of life in these patients. In this review, we examine how recent advances in the use of new diagnostic techniques have led to improved understanding of the link between nail and musculoskeletal manifestations of psoriatic disease (PsD; e.g., enthesitis, arthritis) and we review targeted therapies for nail PsO (NP).Methods: We performed a literature search to identify which systemic therapies approved for the treatment of PsO and/or psoriatic arthritis (PsA) have been evaluated for the treatment of NP, either as a primary or secondary outcome. A total of 1546 articles were identified on February18, 2019, and evaluated for relevance.Results: We included findings from 66 articles on systemic therapies for the treatment of NP in PsD. With several scoring systems available for the evaluation of psoriatic nail disease, including varied subtypes and application of the Nail Psoriasis Area Severity Index, there was a high level of methodological heterogeneity across studies.Conclusion: NP is an important predictor of enthesitis, which is associated with the early stages of PsA; therefore, it is important for rheumatologists and dermatologists to accurately diagnose and treat NP to prevent nail damage and potentially delay the onset and progression of joint disease. Further research is needed to address the lack of both standardized NP scoring systems and well-defined treatment guidelines to improve management of PsD.